# Vijaya Diagnostic Centre (VIJAYA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/vijaya

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,470.8
- Change: +2.30%
- As of: 2026-11-06
- 1D return: +2.30%
- 5D return: +1.74%
- 1M return: +2.77%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

VIJAYA closed at ₹1470.8 on 2026-11-06, trading near the upper end of its 20-day (+79.9%) and 52-week (+83.5%) ranges. The daily technical setup is mixed: while price remains above all major moving averages (EMA/SMA 20/50/200), it sits below the Supertrend indicator, which signals a bearish bias. Daily trend strength is weak (ADX 14.45), suggesting a lack of conviction despite recent positive returns (+2.3% in one day, +5.9% over ten days). A Bullish Engulfing Reversal pattern formed today, potentially signaling a short-term bounce after an extreme volume-driven downward anomaly on 2026-11-04. However, monthly momentum remains constructive with a bullish Supertrend and developing trend strength (ADX 21.07). Risk is elevated, with annualized volatility at 40.1% and a current drawdown of -6.4%. Immediate resistance lies at ₹1490.3 (+1.33%), while support is found at ₹1464.0 (-0.46%).

- Trend Conflict: Daily structure shows price above MAs but below Supertrend (bearish signal) with weak momentum (ADX 14.45), contrasting with a stronger weekly trend (ADX 36.13, bullish Supertrend).
- Price Action: Closed at ₹1470.8; formed a Bullish Engulfing Reversal on 2026-11-06 following an extreme volume drop on 2026-11-04.
- Key Levels: Resistance at ₹1490.3 (+1.33%) and ₹1501.0 (+2.05%); Support at ₹1464.0 (-0.46%) and ₹1438.2 (-2.22%).
- Risk Profile: High volatility (40.1% annualized) and current drawdown of -6.4%; stock is trading near multi-month highs.

- Bullish Engulfing Reversal
- Inside Bar
- Evening Star
- Outside Bar
- Doji
- Morning Star

### News Context

Vijaya Diagnostic Centre reported strong financial performance for the second quarter ended October 2026, with net profit rising 37.4% year-on-year to ₹59.5 crore. This growth was underpinned by a 26.7% increase in revenue and significant margin expansion, as EBITDA margins improved by 350 basis points to reach 44.1%. The company attributed these results to higher test volumes and robust performance in its core markets. Beyond domestic operations, Vijaya announced its strategic entry into the North-East region through the acquisition of Arya Wellness Centre in Guwahati.

Despite the positive earnings report, the market reacted negatively on November 4, 2026, with Vijaya’s shares falling 3%, contrasting with a 6% rise in peer Global Health. This divergence suggests that while the fundamental metrics were strong, investor sentiment or specific details within the Q2 results may have triggered a sell-off, highlighting the disconnect between operational growth and short-term price action.

- Q2 Net Profit: Increased 37.4% YoY to ₹59.5 crore, driven by 26.7% revenue growth and EBITDA margin expansion of 350 bps to 44.1%.
- Strategic Expansion: Entered the North-East market via the acquisition of Arya Wellness Centre in Guwahati.
- Market Reaction: Shares declined 3% on November 4, 2026, following the earnings release, diverging from peer Global Health which rose 6%.

- [Price Action: Global Health up 6%, Vijaya Diagnostic down 3% post Q2 earnings](https://www.moneycontrol.com/news/business/markets/price-action-global-health-up-6-vijaya-diagnostic-down-3-post-q2-earnings-14068202.html)
- [Vijaya Diagnostic Q2 Results: Net profit jumps 37% on higher test volumes, margin expansion](https://www.cnbctv18.com/market/stocks/vijaya-diagnostic-centre-share-price-q2-results-net-profit-jumps-37-on-higher-test-volumes-margin-expansion-20026378.htm)

### Official Filings

Vijaya Diagnostic Centre Limited reported unaudited financial results for Q2 and H1 FY2026–27, highlighting strong top-line growth and profitability expansion. Consolidated revenue from operations rose 26.7% year-on-year to ₹2,553.9 million in Q2, with profit after tax increasing 37.4% to ₹594.7 million. For the half-year, revenue grew 24.8% to ₹4,863.7 million, and PAT climbed 37.5% to ₹1,125.7 million. Alongside these figures, the company announced a strategic acquisition via a Business Transfer Agreement to purchase Arya Wellness Centre in Guwahati, Assam, marking its entry into the North-East region. Governance updates include the appointment of Mr. Rahul Jain as Company Secretary and Compliance Officer effective November 03, 2026. The Board also approved the release of investor presentations and audio recordings of earnings calls to ensure transparency.

- Q2 FY27 consolidated revenue reached ₹2,553.9 million (up 26.7% YoY) and PAT was ₹594.7 million (up 37.4% YoY).
- H1 FY27 consolidated revenue stood at ₹4,863.7 million (up 24.8% YoY) with PAT at ₹1,125.7 million (up 37.5% YoY).
- The company entered a Business Transfer Agreement to acquire Arya Wellness Centre in Guwahati, Assam, expanding its geographic footprint to the North-East.
- Mr. Rahul Jain was appointed as Company Secretary and Compliance Officer effective November 03, 2026, following Nomination and Remuneration Committee recommendation.

- [Vijaya Diagnostic Centre Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/VIJAYA_05112026113553_Signed_Newspaper_STX_051126.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/VIJAYA_04112026164629_VDCL_EC_Audio_Recording_04112026.pdf)
- [Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026195557_VDCL_BM_Ootcome_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange regarding Appointment of Mr Rahul Jain as Company Secretary & Compliance Officer of the company w.e.f. November 03, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026201817_Signed_VDCL_CS_appointment_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press Release on Q2 FY2027 Results". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026202818_VDCL_PR_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026203436_VDCL_Investor_Pres_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_19532_WebXMLFile_20261103_204318925.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752300_03112026092343_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752297_03112026092338_WEB.xml)
- [Financial Results |Meeting Date: 03-Nov-2026](https://nsearchives.nseindia.com/corporate/VIJAYA_28102026100016_Stx_Intimation_BM_03112026.pdf)

### Fundamentals

Vijaya Diagnostic Centre demonstrates a robust expansion trajectory, with total assets growing from ₹1,391 crore in September 2025 to ₹1,733 crore by September 2026. This growth is underpinned by strong operational momentum; Q2 FY2026-27 revenue reached ₹255 crore, up sequentially from ₹231 crore in Q1, while Profit Before Tax rose to ₹79.4 crore from ₹70.9 crore. Earnings quality remains high, evidenced by a Cash Flow from Operations/EBITDA ratio consistently above 96% over the last three years and a negative Cash Conversion Cycle (–117 days as of Mar 2026), indicating efficient working capital management.

Financial health is supported by rising equity (₹1,057 crore) and stable return metrics, including a 21% ROCE. However, borrowing has increased significantly, rising from ₹259 crore in Mar 2024 to ₹423 crore in Mar 2026, coinciding with higher finance costs (₹11.4 crore in Q2 FY26-27). Shareholding patterns show a notable shift: DIIs increased their stake to 32.49% in Sep 2026, while FIIs reduced theirs to 10.67%. The key checkpoint is monitoring whether the expanding asset base translates into sustained operating leverage as debt levels continue to rise.

- Revenue grew sequentially to ₹255 crore in Q2 FY2026-27, with PBT increasing to ₹79.4 crore.
- Total assets expanded to ₹1,733 crore (Sep 2026), driven by non-current assets rising to ₹1,284 crore.
- Borrowings have more than doubled since Mar 2024 (₹259 crore to ₹423 crore), raising finance costs to ₹11.4 crore in Q2 FY26-27.
- DIIs increased holdings to 32.49% in Sep 2026, while FIIs reduced stakes to 10.67%.

### Bull Case

Vijaya Diagnostic Centre presents a conditional upside case anchored by robust operational momentum and multi-timeframe technical alignment, despite recent short-term price weakness. In the second quarter ended November 2026, the company delivered a 37.4% year-on-year increase in net profit to ₹59.5 crore, driven by a 26.7% revenue rise and significant margin expansion. EBITDA margins improved by 350 basis points to 44.1%, reflecting strong performance in core markets and higher test volumes. This fundamental strength is complemented by strategic geographic expansion through the acquisition of Arya Wellness Centre in Guwahati, signaling entry into the North-East region.

Technically, while the daily trend is bearish with the stock down 3% post-earnings, the weekly and monthly trends remain bullish. The weekly Supertrend is positive, and the stock has maintained strong relative performance over longer horizons, including a +44.5% return over the past year and +41.1% year-to-date. Key resistance levels at ₹1,490.3 and ₹1,501.0 represent immediate hurdles; a sustained move above these levels could validate the broader bullish structure. Investors should monitor whether the company can translate its margin efficiency and regional expansion into continued earnings growth to overcome near-term volatility.

- Q2 Net profit surged 37.4% YoY to ₹59.5 crore, supported by a 26.7% revenue increase and EBITDA margin expansion of 350 bps to 44.1%.
- Weekly and monthly technical trends are bullish, contrasting with the daily bearish signal, indicating potential for recovery if key resistance levels are breached.
- Strategic expansion into the North-East via the acquisition of Arya Wellness Centre in Guwahati provides a new growth vector beyond core markets.
- Stock remains within a long-term uptrend with +44.5% returns over the past year, though it faces immediate resistance at ₹1,490.3 and ₹1,501.0.

- [Price Action: Global Health up 6%, Vijaya Diagnostic down 3% post Q2 earnings](https://www.moneycontrol.com/news/business/markets/price-action-global-health-up-6-vijaya-diagnostic-down-3-post-q2-earnings-14068202.html)
- [Vijaya Diagnostic Q2 Results: Net profit jumps 37% on higher test volumes, margin expansion](https://www.cnbctv18.com/market/stocks/vijaya-diagnostic-centre-share-price-q2-results-net-profit-jumps-37-on-higher-test-volumes-margin-expansion-20026378.htm)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/VIJAYA_05112026113553_Signed_Newspaper_STX_051126.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/VIJAYA_04112026164629_VDCL_EC_Audio_Recording_04112026.pdf)
- [Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026195557_VDCL_BM_Ootcome_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange regarding Appointment of Mr Rahul Jain as Company Secretary & Compliance Officer of the company w.e.f. November 03, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026201817_Signed_VDCL_CS_appointment_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press Release on Q2 FY2027 Results". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026202818_VDCL_PR_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026203436_VDCL_Investor_Pres_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_19532_WebXMLFile_20261103_204318925.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752300_03112026092343_WEB.xml)

### Bear Case

Vijaya Diagnostic Centre faces near-term technical headwinds despite strong underlying profitability. Following its Q2 earnings release, which reported a 37.4% year-on-year profit increase to ₹59.5 crore, the stock price fell 3%, indicating that market participants may be pricing in caution or taking profits after significant prior gains. The daily technical setup is currently bearish, with the SuperTrend indicator signaling downside pressure and the 50-day simple moving average (SMA) slope at -4.42, suggesting a short-term trend reversal. Price action has pulled back from recent highs, with the stock trading at ₹1,470.8 against immediate resistance at ₹1,490.3 (1.33% above). While the monthly trend remains bullish, the divergence between long-term momentum and short-term weakness highlights a period of consolidation or correction. Investors should monitor whether the stock holds above the pivot support level at ₹1,438.2; a break below this level could expose further downside toward the low support at ₹1,411.9.

- Post-earnings price decline: Stock fell 3% following Q2 results reporting ₹59.5 crore net profit (+37.4% YoY), suggesting profit-taking or cautious sentiment despite margin expansion to 44.1%.
- Bearish daily technicals: Daily SuperTrend is bearish, and the 50-day SMA slope is negative (-4.42), contrasting with the bullish monthly trend.
- Resistance overhead: Immediate resistance sits at ₹1,490.3 (1.33% above current price), limiting upside potential in the near term.
- Support monitoring: Key pivot support is at ₹1,438.2; failure to hold this level exposes the stock to lower support at ₹1,411.9.

- [Price Action: Global Health up 6%, Vijaya Diagnostic down 3% post Q2 earnings](https://www.moneycontrol.com/news/business/markets/price-action-global-health-up-6-vijaya-diagnostic-down-3-post-q2-earnings-14068202.html)
- [Vijaya Diagnostic Q2 Results: Net profit jumps 37% on higher test volumes, margin expansion](https://www.cnbctv18.com/market/stocks/vijaya-diagnostic-centre-share-price-q2-results-net-profit-jumps-37-on-higher-test-volumes-margin-expansion-20026378.htm)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/VIJAYA_05112026113553_Signed_Newspaper_STX_051126.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/VIJAYA_04112026164629_VDCL_EC_Audio_Recording_04112026.pdf)
- [Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026195557_VDCL_BM_Ootcome_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange regarding Appointment of Mr Rahul Jain as Company Secretary & Compliance Officer of the company w.e.f. November 03, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026201817_Signed_VDCL_CS_appointment_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press Release on Q2 FY2027 Results". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026202818_VDCL_PR_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026203436_VDCL_Investor_Pres_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_19532_WebXMLFile_20261103_204318925.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752300_03112026092343_WEB.xml)

### FAQs

**How did Vijaya Diagnostic Centre perform financially in Q2 FY2027?**

For the quarter ended September 30, 2026, Vijaya reported consolidated revenue from operations of ₹2,553.9 million, up 26.7% year-on-year. Profit after tax rose 37.4% to ₹594.7 million, driven by higher test volumes and a 350 basis point expansion in EBITDA margins to 44.1%.

**What strategic expansion did the company announce during the quarter?**

The company entered the North-East region through the acquisition of Arya Wellness Centre in Guwahati, Assam. This move was formalized via a Business Transfer Agreement signed during the quarter, marking its first entry into this geographic market.

**How has the stock price reacted to these results?**

Following the earnings release, the stock fell 3%, closing at ₹1,470.8 on November 6, 2026. This contrasts with peer Global Health, which rose 6% post-results. The stock remains within a monthly bullish trend but faces resistance near ₹1,490.

**Are there any recent changes in key management personnel?**

Yes. Effective November 3, 2026, the Board appointed Mr. Rahul Jain (ICSI M. No. A62949) as Company Secretary and Compliance Officer, designated as Key Managerial Personnel, following a recommendation from the Nomination and Remuneration Committee.

- [Price Action: Global Health up 6%, Vijaya Diagnostic down 3% post Q2 earnings](https://www.moneycontrol.com/news/business/markets/price-action-global-health-up-6-vijaya-diagnostic-down-3-post-q2-earnings-14068202.html)
- [Vijaya Diagnostic Q2 Results: Net profit jumps 37% on higher test volumes, margin expansion](https://www.cnbctv18.com/market/stocks/vijaya-diagnostic-centre-share-price-q2-results-net-profit-jumps-37-on-higher-test-volumes-margin-expansion-20026378.htm)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/VIJAYA_05112026113553_Signed_Newspaper_STX_051126.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/VIJAYA_04112026164629_VDCL_EC_Audio_Recording_04112026.pdf)
- [Vijaya Diagnostic Centre Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026195557_VDCL_BM_Ootcome_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange regarding Appointment of Mr Rahul Jain as Company Secretary & Compliance Officer of the company w.e.f. November 03, 2026. |SUBJECT: Appointment](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026201817_Signed_VDCL_CS_appointment_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press Release on Q2 FY2027 Results". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026202818_VDCL_PR_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026203436_VDCL_Investor_Pres_03112026.pdf)
- [Vijaya Diagnostic Centre Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_19532_WebXMLFile_20261103_204318925.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752300_03112026092343_WEB.xml)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,438.2
- Risk regime: Price Risk Currently Contained

### Support levels
- 1334.525
- 1303.2
- 1285.55

### Resistance levels
- 1501
- 1530
- 1584.55

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +2.30% |
| return_10 | +5.86% |
| return_1m | +0.28% |
| return_1y | +44.47% |
| return_20 | +2.77% |
| return_3m | +7.37% |
| return_5 | +1.74% |
| return_6m | +23.56% |
| return_since_start | +38.40% |
| return_ytd | +41.10% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -30.63% |
| annualized_volatility | +40.08% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Vijaya Diagnostic Centre Limited Q2 FY2026-27: Revenue rises 27%, profit 37%

Revenue from operations increased 26.7% year on year to ₹255.39 crore in Q2 FY2026-27, while profit for the period rose 37.4% to ₹59.47 crore. Expenses grew more slowly than revenue both year on year and sequentially; operating cash flow was ₹181.76 crore, alongside ₹164.52 crore of cash used in investing activities.

## Revenue and income

Revenue from operations was ₹255.39 crore, up 10.6% from ₹230.98 crore in Q1 FY2026-27 and 26.7% from ₹201.56 crore in Q2 FY2025-26. The reported quarterly series shows revenue increasing for five consecutive quarters. Total income was ₹260.34 crore, including other income of ₹4.95 crore.

## Costs and profitability

Total expenses increased 7.3% sequentially to ₹180.92 crore, below the 10.6% growth in revenue. Other expenses rose 9.6% to ₹76.03 crore and finance costs increased 3.4% to ₹11.38 crore.

Profit before tax was ₹79.42 crore, up 11.9% from Q1 FY2026-27 and 37.0% from ₹57.98 crore in Q2 FY2025-26. Profit for the period increased 12.0% sequentially and 37.4% year on year, to ₹59.47 crore. Year-on-year expenses growth was 20.8%, also below revenue growth.

## Tax and per-share earnings

Tax expense rose 11.8% sequentially to ₹19.94 crore. Basic EPS from continuing operations was ₹5.78, compared with ₹5.16 in Q1 FY2026-27 and ₹4.21 in Q2 FY2025-26. Diluted EPS from continuing operations was ₹5.76, versus ₹5.15 and ₹4.20, respectively. Trailing twelve-month EPS was ₹19.80.

## Cash flow and liquidity

Operating cash flow was ₹181.76 crore in the quarter. Investing activities used ₹164.52 crore and financing activities used ₹46.84 crore; reported free cash flow was ₹17.24 crore. Cash and cash equivalents stood at ₹10.08 crore on 30 September 2026, down from ₹39.68 crore at 31 March 2026. The company also held ₹34.59 crore in other bank balances and ₹304.01 crore in current investments at quarter end.

## Balance sheet and asset base

Total assets increased to ₹1,733.35 crore at 30 September 2026 from ₹1,507.05 crore at 31 March 2026. Property, plant and equipment rose to ₹1,044.59 crore from ₹929.62 crore, while capital work in progress decreased to ₹32.97 crore from ₹34.29 crore. Equity increased to ₹1,057.33 crore from ₹957.15 crore, and noncurrent financial liabilities rose to ₹486.23 crore from ₹400.03 crore.

## Key Takeaway

Revenue growth accelerated the quarter’s earnings advance: profit for the period grew faster than sales as expenses increased more slowly than revenue. Operating cash flow was substantial, while investing and financing outflows accompanied a decline in cash and cash equivalents since March; current investments stood at ₹304.01 crore at quarter end.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +52.46%
- FII holding: +10.67%
- DII holding: +32.49%
- Mutual fund holding: +31.44%
- Retail holding: +3.55%
- Promoter pledged: +0.00%

### Major reported shareholders

- SURENDRANATH REDDY SURA — +32.20%
- SUPRITA SURA REDDY — +8.71%
- SUNIL CHANDRA KONDAPALLY — +7.55%
- KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK BUSINESS C — +6.59%
- HDFC MUTUAL FUND - HDFC CHILDRENS FUND — +5.57%
- NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA MUL — +4.53%
- GEETHA REDDY SURA — +3.94%
- HSBC MUTUAL FUND - HSBC AGGRESSIVE HYBRID FUND — +3.43%
- AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL F — +3.42%
- ICICI PRUDENTIAL SMALLCAP INDEX FUND — +2.56%

## Official filings

- 2026-11-06 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_06112026183109_Signed_Transcript_Q2_061126.pdf)
- 2026-11-05 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_05112026113553_Signed_Newspaper_STX_051126.pdf)
- 2026-11-04 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_04112026164629_VDCL_EC_Audio_Recording_04112026.pdf)
- 2026-11-03 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026195557_VDCL_BM_Ootcome_03112026.pdf)
- 2026-11-03 — Management Change: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026201817_Signed_VDCL_CS_appointment_03112026.pdf)
- 2026-11-03 — Press Release: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026202818_VDCL_PR_03112026.pdf)
- 2026-11-03 — Earnings Presentation: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_03112026203436_VDCL_Investor_Pres_03112026.pdf)
- 2026-11-03 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_19532_WebXMLFile_20261103_204318925.xml)
- 2026-11-03 — Financial Results Filing: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752300_03112026092343_WEB.xml)
- 2026-11-03 — Financial Results Filing: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752297_03112026092338_WEB.xml)
- 2026-10-28 — Board Meeting Notice: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_28102026100016_Stx_Intimation_BM_03112026.pdf)
- 2026-10-28 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_28102026101523_VIJAYA_EC_STX_SUBMISSION_04112026.pdf)
- 2026-10-28 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_19532_WebXMLFile_20261028_102451469.xml)
- 2026-10-28 — Board Meeting Notice: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_19532_WebXMLFile_20261028_102451469.xml)
- 2026-10-28 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_19532_WebXMLFile_20261028_142926767.xml)
- 2026-10-12 — Shareholding Disclosure: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1735976_12102026015530_WEB.xml)
- 2026-10-06 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_06102026140819_Stx_Intimation_Signed.pdf)
- 2026-09-28 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_19532_WebXMLFile_20260928_165236389.xml)
- 2026-09-28 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_28092026170129_Stx_Intimation_Signed.pdf)
- 2026-09-24 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_24092026161753_Stx_Intimation_Signed.pdf)
- 2026-09-15 — Corporate Action Notice: Vijaya Diagnostic Centre Limited - Ex-Date: 16-Sep-2026 — [Official attachment](https://www.nseindia.com/companies-listing/corporate-filings-actions)
- 2026-09-11 — Agreement Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/VIJAYA_11092026195905_Stx_BM_Outcome_Acquisition_Signed.pdf)
- 2026-09-11 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_19532_WebXMLFile_20260911_200716296.xml)
- 2026-09-11 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_19532_WebXMLFile_20260911_201212136.xml)
- 2026-09-11 — Generic Announcement: Vijaya Diagnostic Centre Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_19532_WebXMLFile_20260911_201241773.xml)

## News and market events

- 2026-11-04 — MONEYCONTROL: **Price Action: Global Health up 6%, Vijaya Diagnostic down 3% post Q2 earnings** — Global Health shares rose 6% while Vijaya Diagnostic fell 3% following the release of their second-quarter earnings results. The price action reflects market reactions to the respective financial performance reported by these listed entities. — [Source](https://www.moneycontrol.com/news/business/markets/price-action-global-health-up-6-vijaya-diagnostic-down-3-post-q2-earnings-14068202.html)
- 2026-11-03 — CNBC-TV18: **Vijaya Diagnostic Q2 Results: Net profit jumps 37% on higher test volumes, margin expansion** — Vijaya Diagnostic Centre reported a 37.4% year-on-year increase in Q2 net profit to ₹59.5 crore, driven by a 26.7% rise in revenue and a 350 basis point expansion in EBITDA margins to 44.1%. The company attributed this growth to higher test volumes and strong performance in core markets, while also announcing its entry into the North-East region through the acquisition of Arya Wellness Centre in Guwahati. — [Source](https://www.cnbctv18.com/market/stocks/vijaya-diagnostic-centre-share-price-q2-results-net-profit-jumps-37-on-higher-test-volumes-margin-expansion-20026378.htm)
- 2026-09-24 — MONEYCONTROL: **Trade Spotlight: How should you trade Vijaya Diagnostic Centre, IDFC First Bank, Radico Khaitan, MCX India, Phoenix Mills, and others on September 24?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Vijaya Diagnostic Centre,Somany Ceramics,IDFC First Bank,Radico Khaitan,Phoenix Mills,Multi Commodity Exchange of India — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-vijaya-diagnostic-centre-idfc-first-bank-radico-khaitan-mcx-india-phoenix-mills-and-others-on-september-24-14036848.html)
- 2026-09-24 — Mint: **Raja Venkatraman recommends three stocks for 24 September** — Market expert Raja Venkatraman shares his top stock picks for 24 September. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-24-september-11790177527677.html)
- 2026-09-22 — BUSINESSTODAY: **L&T, DRL, Vijaya Diagnostic, M&M Financial: Buy, Hold or Sell? Here are target prices** — L&T shares, Dr Reddy's Laboratories shares, Vijaya Diagnostic Centre shares, Mahindra & Mahindra Financial Services shares, M&M Finance shares, Antique Stock Broking, stock target prices, Buy rating, Hold rating, brokerage recommendations, valuation, share price target — [Source](https://www.businesstoday.in/markets/stocks/story/lt-drl-vijaya-diagnostic-mm-financial-buy-hold-or-sell-here-are-target-prices-557064-2026-09-22)
- 2026-09-15 — BUSINESSTODAY: **Hindustan Copper, Garware Hi-Tech Films, Vijaya Diagnostic Centre among stocks to turn ex-dividend on September 16** — Hindustan Copper, Garware Hi-Tech Films, Vijaya Diagnostic Centre, Vinati Organics, VST Tillers Tractors, Bannari Amman Sugars, Indo Tech Transformers, Eldeco Housing & Industries, TANFAC Industries, ex-dividend stocks, dividend stocks, September 16 ex-dividend, highest dividend stocks, final dividend, dividend record date — [Source](https://www.businesstoday.in/markets/stocks/story/hindustan-copper-garware-hi-tech-films-vijaya-diagnostic-centre-among-stocks-to-turn-ex-dividend-on-september-16-555645-2026-09-15)
- 2026-09-13 — BUSINESS: **Robust demand, pricing to keep volumes strong for diagnostics sector** — Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage — [Source](https://www.business-standard.com/markets/news/markets-news-robust-demand-pricing-to-keep-volumes-strong-for-diagnostics-126091300223_1.html)
- 2026-09-01 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —1 September 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today —Lumax AutoTechnologies, Vijaya Diagnostic Centre, Tamilnad Mercantile Bank, EPL, and Sansera Engineering. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-1-september-2026-11788224482286.html)
- 2026-08-10 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty around 24,600; Paytm shares jump 8%** — Sensex Today | Stock Market LIVE Updates: We are at the halfway mark of the first day of trade, and the markets are trading in a volatile space, as the Nifty index remains cautious. The index is looking to hold onto the 24,500 mark. The Nifty Bank is also under pressure, down 100 points. SBI, Adani Ports and HDFC Life are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-banks-midcaps-bajaj-fin-pfc-kaynes-ola-bharat-forge-share-price-liveblog-19965161.htm)
- 2026-08-07 — The Hindu: **Q1 Results 07th Aug Live: SBI, Titan, Hindalco, Hitachi Energy, Power Finance Corporation, Godrej Consumer, Oil India, NLC, Cupid, Kaynes Tech, Ramco Cements, Afcons Infra, Lemon Tree Hotels, Cello to announce Q1 results, LIC, Hero Motocorp, Britannia, Siemens Energy, Muthoot Microfin shares gain, Trent, Premier Energies decline after Q1** — Q1 Results Today, 07th August 2026 Live Updates: Find all the latest Q1 results 2026 updates of Aarti Pharmalabs, Advait Energy Transitions, Amba Enterprises, Afcons Infrastructure, AG Ventures, Akshar Spintex, Alankit, Anuh Pharma, APM Industries, Aqylon Nexus, Archidply Industries, Arihant Superstructures, Arnold Holdings, Aro Granite Industries, Arvind SmartSpaces, Aryan Share and Stock Brokers, Asarfi Hospital, Ashapura Minechem, Ashirwad Steels & Industries, Asit C Mehta Financial Services,... — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-sbi-titan-hindalco-power-finance-corporation-godrej-consumer-oil-india-nlc-kaynes-tech-ramco-cements-afcons-infra-lemon-tree-cello-hitachi-lic-trent-results-07-august-202/article71313123.ece)
- 2026-08-07 — MONEYCONTROL: **Stocks to Watch Today: Alkem Labs, J Kumar Infra, Dabur, Britannia, Siemens Energy, Shipping Corporation, Vijaya Diagnostic Centre in focus on 7 August** — Stocks to watch, stocks in focus today, stocks in focus, share market today, top stocks, shares in focus today, shares today, today stocks to watch, trending stocks, trending stocks today, markets today, buzzing stocks, stocks today, stock market today,Britannia Industries,Siemens Energy India,Life Insurance Corporation of India,Shipping Corporation of India,Vijaya Diagnostic Centre,Apollo Tyres,Premier Energies,Alkem Laboratories,J Kumar Infraprojects,Aegis Logistics,Aegis Vopak Terminals,Dabur India,Neuland Laboratories,Orient Electric,Shadowfax Technologies,KPIT Technologies,CreditAccess Grameen,Indegene,Bandhan Bank — [Source](https://www.moneycontrol.com/news/business/markets/stocks-to-watch-today-alkem-labs-j-kumar-infra-dabur-britannia-siemens-energy-shipping-corporation-vijaya-diagnostic-centre-in-focus-on-7-august-13997019.html)
- 2026-08-07 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Jubilant FoodWorks (₹473.75)** — Sensex, Nifty, Share Prices Live: The stock of Jubilant FoodWorks has been rallying over the past two weeks. On Monday, it broke out of a resistance at ₹456, hit a four-month high of ₹495.10 on Wednesday and has now moderated to ₹473.75. Therefore, traders can go long now at ₹473 and buy more shares if the price drops to ₹460. Place initial stop-loss at ₹430. When the stock hits ₹550, revise the stop-loss to ₹525. On a rally to ₹575, raise the stop-loss to ₹550. Book profits at ₹600. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-7th-august-2026/article71314561.ece)
- 2026-08-06 — CNBC-TV18: **Q1 Results LIVE Updates: Muthoot Microfin profit surges; Fortis Healthcare margin contracts** — Q1 Results LIVE Updates; Trent, Britannia, Lupin, Samvardhana Motherson, Apollo Tyres, Blue Star, Premier Energies, HCC, NCC, PG Electroplast, Emcure Pharma, Firstsource Solutions are some of the many companies that will be reporting their results during the course of Thursday's trading session on Dalal Street. Result reactions today come from PB Fintech, Aurobindo Pharma, Cummins India, GE Vernova T&D, ION Exchange and many others. Watch this space for all the LIVE Q1 result updates, management and brokerage commentary along with stock moves. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-cummins-ge-vernova-td-pb-fintech-trent-britannia-hero-lupin-samil-pgel-apollo-tyres-sci-ncc-hcc-premier-energies-share-price-liveblog-19962840.htm)
- 2026-07-17 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty extends gains, rises above 24,250 mark** — Sensex Today | Stock Market LIVE Updates: The markets, contrary to indicators, are trading on a strong footing. The Nifty index is surging with gains of over 120 points as it looks to close the week on a high.The Nifty Bank is also trading higher, rising over 200 points, now above 57,800.Jio Fin, Tech Mahindra and Infosys are the top gainers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-ril-wipro-tech-mah-jio-fin-federal-bank-havells-it-share-price-liveblog-19947678.htm)

## Business profile

**Strategic vision:** Integrated diagnostic chain providing laboratory and radiology services.

### Business segments
- **Diagnostic Services:** Provides a comprehensive range of diagnostic services, encompassing both laboratory and radiology testing through a network of diagnostic centres.

### Competitive strengths
- Extensive network of diagnostic centres across multiple Indian states.
- Comprehensive range of laboratory and radiology services.
- Experienced team of over 300 specialized doctors.

## Related stocks

- [Blue Jet Healthcare Limited (Healthcare)](https://faxioms.com/stocks/bluejet) — -3.23%
- [Caplin Point Laboratories Limited (Healthcare)](https://faxioms.com/stocks/caplipoint) — -1.64%
- [Cohance Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/cohance) — -3.56%
- [Concord Biotech Limited (Healthcare)](https://faxioms.com/stocks/concordbio) — -6.64%
- [Eris Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/eris) — +0.58%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/vijaya
Markdown representation: https://faxioms.com/stocks/vijaya?render=md